Magnendo

Magnendo Corp. is an MIT spinout developing a robotic navigation platform for neuro-endovascular intervention. The system pairs magnetically steerable soft-robotic guidewires with robotic control, advanced medical imaging and intelligent navigation software, with the aim of helping physicians reach targets in the brain's complex and tortuous vasculature faster and more consistently. The company frames the clinical problem as the difficulty of navigating from the vascular access site to a clot or aneurysm: slow or difficult target access delays treatment for stroke patients, while tortuous anatomy raises the risk of complications such as vessel perforation or dissection.

The platform is positioned as compatible with existing clinical workflows and commercially available devices. Stated objectives include shortening procedure times, reducing unsafe maneuvers that can lead to hemorrhagic complications, improving consistency across operators and patient anatomies, and lowering the cost of neuroendovascular care. As of mid-2026 the company reported preclinical validation of its robotic system and magnetic guidewires and was working toward productization and a first clinical platform for first-in-human studies.

Founding story

The technology originated in years of research and development at MIT. CEO Yoonho Kim is described as the inventor and technical lead, and MIT mechanical engineering professor Xuanhe Zhao is described as co-inventor and scientific advisor. The underlying work is reflected in publications on printed ferromagnetic domains for untethered fast-transforming soft materials (Nature, 2018), ferromagnetic soft continuum robots (Science Robotics, 2019), and telerobotic neurovascular interventions with magnetic manipulation (Science Robotics, 2022).

Traction

Magnendo reports preclinical results generated with leading neurointerventional physicians indicating the potential to substantially reduce navigation times and improve procedural consistency across operators and anatomies. The company states its platform has been validated by key opinion leaders in neurointervention and that it is preparing its first clinical system ahead of first-in-human studies.

Latest developments

In July 2026 Magnendo announced an $18 million Series A led by Penumbra, Inc. with participation from new and existing institutional investors, to fund productization and preparation for first-in-human clinical studies. Its careers site simultaneously listed roughly fifteen full-time openings in Newton, Massachusetts spanning robotics, computer vision, medical device software, systems engineering, process development and program management.